 Dalteparin
"Dalteparin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Descriptor ID |
D017985
|
| MeSH Number(s) |
D09.698.373.400.300.150
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dalteparin".
Below are MeSH descriptors whose meaning is more specific than "Dalteparin".
This graph shows the total number of publications written about "Dalteparin" by people in this website by year, and whether "Dalteparin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 | | 2010 | 0 | 1 | 1 | | 2013 | 2 | 0 | 2 | | 2014 | 1 | 0 | 1 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Dalteparin" by people in Profiles.
-
Golightly LK, Simendinger BA, Kiser TH. Cancer-associated thromboembolism: antithrombotic management of hospitalized patients. J Thromb Thrombolysis. 2020 Jan; 49(1):59-66.
-
Clark NP, Douketis JD, Hasselblad V, Schulman S, Kindzelski AL, Ortel TL. Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial. Am Heart J. 2018 Jan; 195:108-114.
-
Gillespie MA, Lyle CA, Goldenberg NA. Updates in pediatric venous thromboembolism. Curr Opin Hematol. 2015 Sep; 22(5):413-9.
-
Babilonia KM, Golightly LK, Gutman JA, Hassell KL, Kaiser JN, Kiser TH, Klem PM, Trujillo TC. Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalization. Clin Appl Thromb Hemost. 2014 Nov; 20(8):799-806.
-
Anderson DR, Dunbar MJ, Kahn SR. Aspirin versus low-molecular-weight heparin after total hip arthroplasty. Ann Intern Med. 2013 Oct 01; 159(7):502-3.
-
Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D, Fisher W, Gofton W, Gross P, Pelet S, Crowther M, MacDonald S, Kim P, Pleasance S, Davis N, Andreou P, Wells P, Kovacs M, Rodger MA, Ramsay T, Carrier M, Vendittoli PA. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013 Jun 04; 158(11):800-6.
-
Monte AA, Bodmer M, Schaeffer TH. Low-molecular-weight heparin overdose: management by observation. Ann Pharmacother. 2010 Nov; 44(11):1836-9.
-
Haines ST, Dager WE, Trujillo TC. Clinical and management challenges in preventing venous thromboembolism in health systems: a case-based panel discussion. Am J Health Syst Pharm. 2010 May 15; 67(10 Suppl 6):S26-30.
-
Goldenberg NA, Jacobson L, Hathaway H, Tripputi M, Primeaux J, Child J. Anti-Xa stability of diluted dalteparin for pediatric use. Ann Pharmacother. 2008 Apr; 42(4):511-5.
-
Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol. 2004 Sep; 191(3):1024-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|